CHYM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CHYM is not a good buy right now for a beginner long-term investor, even with $50,000-$100,000 to deploy. The stock has decent growth fundamentals and positive analyst support, but the current technical setup is weak and there is no proprietary buy signal today. My direct view is to hold off and wait for a better entry rather than buy immediately.
Price closed at 17.205, slightly below the previous close of 17.25, and the broader trend remains weak. MACD histogram is negative at -0.00396 and still contracting, RSI_6 is neutral at 44.773, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That setup points to a down-to-sideways trend rather than a strong upward breakout. Key levels: pivot 17.82, resistance at 19.308 and 20.227, support at 16.332 and 15.413. The stock is not showing a clean technical buy signal.
Analysts remain constructive, with multiple recent initiations and upgrades around the $25-$31 price target range, suggesting meaningful upside from the current price. Options sentiment is also bullish, and the company continues to be described as a fast-growing challenger bank with strong liquidity.
The stock price action is weak relative to the analyst targets, and the chart structure remains bearish. FY 2025 still showed a large net loss of close to $1 billion and a negative net margin of 46.2%, so profitability is not yet durable. The business model depends heavily on partnerships, which is a structural risk mentioned in the news. There is also no confirmed AI Stock Picker or SwingMax signal today, and no notable insider, hedge fund, politician, or congress trading activity to reinforce a fresh buy case.
Latest quarter season was Q1 2026, and the provided news says Chime achieved its first quarter of profitability in that period. For FY 2025, revenue grew 30.7% to nearly $2.2 billion, which is strong top-line growth. But full-year net loss remained close to $1 billion, showing that the company is still in an early scaling phase rather than a consistently profitable business.
Analyst sentiment is favorable and improving. Morgan Stanley raised its price target to $31 from $30 and kept Overweight. BMO initiated at Outperform with a $30 target, Texas Capital initiated at Buy with a $28 target, Wells Fargo initiated at Overweight with a $25 target, and Compass Point upgraded to Buy with a $27 target. Overall, Wall Street pros are constructive on growth and monetization upside, but the stock’s current price action has not yet caught up to that optimism.
